Regulation of BAX/BCL2 gene expression in breast cancer cells by docetaxel-loaded human serum albumin nanoparticles
- 564 Downloads
Today, using nanoparticle-based drug delivery systems has expanded to avoid anticancer side effects. Taxanes are important chemotherapeutic agents in the treatment of metastatic breast cancer. In this study, docetaxel (DTX)-loaded human serum albumin (HSA) nanoparticles (NPs) were prepared and characterized. Drug toxicity of the nanoparticles was measured by MTT assay with different drug concentrations (0.01, 0.1, 0.5, 1 and 5 μM) at different incubation times (24, 48 and 72 h). Expression of BAX/BCL2 mRNA levels was determined by real-time PCR. The size of NPs prepared and used in our study was about 147 nm with surface charge of −29.6 mV. Results obtained from MTT assay showed that 0.5 μM of free drug had 50 % toxicity on MCF-7 cells after 48-h incubation. Real-time PCR results showed an increase in expression of BAX and no change for BCL2. In conclusion, a significant overexpression of BAX gene and changes in BAX/BCL2 ratio were observed for DTX-loaded HSA nanoparticles compared with free DTX and may provide a potential therapy to inhibit anticancer drug resistance.
KeywordsBreast cancer Docetaxel Nanoparticles BAX BCL2
Conflict of interest
The authors declare that they have no conflict of interest.
- 2.Fridman A, Chirokov A, Gutsol A. Non-thermal atmospheric pressure discharges. Phys. 2005;38:R1–24.Google Scholar
- 6.Gumerlock P, Mack P, Gustafsson M, Togonon M, Gandara D. p27 induction as a potential p53-independent mechanism of apoptotic response to docetaxel in non-small cell lung (NSCL) and prostate carcinomas (CaP). Clin Cancer Res. 1999;5:s3859.Google Scholar
- 13.Deim K. Synopsis of plasma proteins scientific tables, vol. 6. DocumentaGeigy: Geigy Pharmaceuticals, Ardsley; 1962.Google Scholar
- 14.Sebak S, Mirzaei M, Malhorta M, Kulamarva A, Prakash S. Human serum albumin nanoparticles as an efficient noscapine drug delivery system for potential use in breast cancer: preparation and in vitro analysis. Int J Nanomed. 2010;5:525–32.Google Scholar
- 16.Giannoukakis N. Current opinion in investigational drugs (London, England: 2000). CJC-1131. 2003;4:1245–9.Google Scholar
- 29.Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A, Tao C, De T, Beals B, Dykes D, Noker P, Yao R, Labao E, Hawkins M, Soon-Shiong P. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res. 2006;12:1317–24.PubMedCrossRefGoogle Scholar
- 31.Miele E, Spinelli GP, Miele E, Tomao F, Tomao S. Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer. Int J Nanoedicine. 2009;4:99–105.Google Scholar